Clinical Trial Eligibility: How Biomarkers and Inclusion Criteria Shape Cancer Treatment

When you hear about a new cancer drug in the news, it’s easy to assume it’s available to everyone. But the truth is, only a fraction of patients can even be considered for these trials-and it’s not just about age or overall health. The real gatekeepers are biomarkers and inclusion criteria. These aren’t just medical jargon. They’re the deciding factors between getting a life-changing treatment and being told you don’t qualify. And for many patients, understanding them is the first step toward taking control of their care.

What Biomarkers Really Do in Cancer Trials

Biomarkers are measurable signs in your body that tell doctors something about your cancer. They could be a gene mutation, a protein level, or even a specific type of cell in your blood. Think of them like a fingerprint for your tumor. Not all cancers are the same, even if they start in the same organ. A lung cancer in one person might be driven by a mutation in the EGFR gene, while another’s is fueled by ALK. These differences matter because treatments work differently on each.

The FDA defines biomarkers as objective measures that show how your body is responding to disease or treatment. There are seven types used in trials: some predict if you’re at risk, others diagnose, monitor, or even tell if a drug will work for you. The most important for eligibility? Predictive and prognostic biomarkers. Predictive ones tell you if a drug will likely help you. Prognostic ones tell you how aggressive your cancer is. Together, they help researchers pick the right patients for the right drugs.

Today, nearly 60% of cancer drugs approved between 2017 and 2022 required biomarker testing before use. That means if you don’t have the right marker, you’re automatically out of the running-even if you’re otherwise healthy. This isn’t arbitrary. Trials using biomarkers to select patients have a nearly 50% success rate in Phase 2, compared to just 27% for trials that don’t. That’s because you’re not throwing a drug at a random group. You’re matching it to the biology of the disease.

How Inclusion Criteria Work-And Why They’re So Strict

Inclusion criteria are the rules that say who can join a trial. They’re not just "you must have cancer." They’re specific: "You must have stage III or IV non-small cell lung cancer with a confirmed KRAS G12C mutation, have not received prior targeted therapy, and have an ECOG performance status of 0 or 1."

Why so detailed? Because trials need clean data. If you include patients with wildly different disease drivers, you can’t tell if the drug worked-or if it just helped one subgroup. Biomarkers help narrow that down. But they also make screening harder. A trial might screen 100 patients to find 15 who meet all the criteria. That’s why some sites report screening failure rates of 70% or more.

Take HER2 as an example. For years, HER2 was only tested in breast cancer. Now, it’s being used in colon, lung, and even bladder cancers. A patient with metastatic colon cancer might be eligible for a HER2-targeted drug trial-but only if their tumor tests positive for HER2 overexpression, their prior treatments are documented, and their liver function is within normal range. Miss one piece, and you’re out.

These criteria protect patients too. If a drug has serious side effects, researchers need to be sure the people taking it have a high chance of benefiting. That means excluding people with other active cancers, heart conditions, or autoimmune diseases-even if those aren’t directly related. It’s not about being "too sick." It’s about keeping the trial safe and meaningful.

The Hidden Challenges: Testing, Timing, and Access

Having a biomarker isn’t enough. You need to prove it. That means getting tested-and that’s where things get messy. Biomarker tests aren’t like a routine blood draw. Some require tissue from a biopsy. Others need a blood sample processed in a special way within hours. If the sample sits too long, or if the lab isn’t CLIA-certified, the results can be wrong.

One study found that 68% of clinical trial sites reported delays of 7 to 14 days for biomarker results. That’s two weeks you could be losing while your cancer progresses. And it’s not just about speed. Different labs use different methods. One site might test for PD-L1 using immunohistochemistry, while another uses next-generation sequencing. Results don’t always match. That’s why 82% of sponsors say inconsistent testing across sites is their biggest headache.

Geography matters too. A biomarker like HLA-A*02:01 is common in Europe but rare in parts of North America. A trial designed in the U.S. might fail to recruit enough patients in rural areas because the marker isn’t prevalent there. That’s why many trials now use centralized labs. They send out standardized kits, collect samples the same way, and run all tests in one place. It’s more expensive-but it’s the only way to ensure reliability.

Why Biomarker Trials Are Winning-And Who’s Leading the Way

The numbers don’t lie. In 2022, 73% of oncology trials included biomarker eligibility criteria. That’s up from 41% in 2017. Why? Because they work. Memorial Sloan Kettering found that using HER2 mutation status to select patients for neratinib increased response rates from 12% to 32%. That’s not a small gain-it’s life-changing.

Companies that invest in biomarker infrastructure see faster enrollment, higher success rates, and better regulatory approval odds. Large pharmaceutical firms run biomarker-driven trials in 68% of their new studies. Smaller biotechs lag behind at 32%, mostly because they can’t afford the testing infrastructure. But that’s changing. New tools like liquid biopsies-blood tests that detect tumor DNA-are making it easier. Instead of invasive tissue biopsies, you can just draw blood. In 2023, 31% of Phase 2+ oncology trials used liquid biopsies. That’s up from just 9% in 2020.

The FDA and EMA now expect biomarkers to be part of trial design. The FDA’s 2023 draft guidance says every new trial must justify whether biomarkers are included or excluded. And it’s not just oncology. Neurology and immunology trials are catching up. By 2025, 65% of new trials are expected to use multi-omic panels-combining genetic, protein, and metabolic data to build a full picture of the disease.

What Patients Need to Know

If you’re considering a clinical trial, ask these questions early:

• What biomarker tests are required? Are they covered by insurance?
• Where will the testing be done? Can I get it done locally, or will I need to travel?
• How long does it take to get results? Will I have to wait weeks before I’m even considered?
• What happens if my test comes back negative? Are there other trials I might qualify for?

Don’t assume your oncologist already knows all the options. Many community clinics still don’t have access to advanced testing. If your hospital doesn’t offer the test, ask if they can refer you to a center that does. Some trials even cover travel costs for patients who need to go elsewhere for screening.

And remember: being told you don’t qualify today doesn’t mean you won’t qualify tomorrow. Biomarkers are evolving fast. A mutation that wasn’t testable last year might be the target of a new drug next year. Stay informed. Talk to patient advocacy groups. Ask about registries that track your cancer type and biomarker status.

The Future Is Personalized-But It’s Not Perfect Yet

Biomarker-driven eligibility isn’t just the future of cancer trials. It’s the present. And it’s working. More patients are getting effective treatments. More drugs are getting approved. More trials are succeeding.

But it’s not fair yet. Access to testing isn’t equal. Rural patients, low-income communities, and non-English speakers still get left behind. The technology exists. The science is solid. What’s missing is the system to deliver it everywhere.

The goal is simple: match the right drug to the right patient at the right time. That’s precision medicine. And with biomarkers leading the way, we’re finally getting closer.